quest diagnostics

Earnings season ramps up this week with quarterly reports due from the likes of tech companies such as IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT), big banks such as Wells Fargo (NYSE: WFC) and Bank of America (NYSE: BAC), and consumer goods giants such as PepsiCo (NYSE: PEP) and Johnson &...

Deutsche Bank reiterates its Hold rating on Quest Diagnostics (NYSE: DGX). At the same time, Deutsche Bank left its price target unchanged at $63. In a research report published today, Deutsche Bank states, "DGX's relative under-performance to its close peer, LH, has grown wider in recent years...

Benchamark reiterated its price target of $9 on Exact Sciences Corporation (NASDAQ: EXAS) in a research report published today. In the report, Benchmark states, "We believe EXAS shares already reflect some anticipation of favorable DDW presentations. Still, we anticipate some support from...

Momentum in equities should parlay into solid performance for larger cap healthcare names such as pharmacy benefit managers, labs and hospitals. In the report, Jefferies writes, “We continue to believe that [Quest Diagnostics] DGX, [Express Scripts, Inc.] ESRX, [Medco Health Solutions, Inc.] MHS (...

Wells Fargo has revised up earnings estimates on CarMax (NYSE: KMX), American Water Works Company (NYSE: AWK), Bill Barrett (NYSE: BBG), First Horizon National (NYSE: FHN), Quest Diagnostics (NYSE: DGX) and Global Payments (NYSE: GPN). It has revised down estimates on DryShips (NASDAQ: DRYS),...

Deutsche Bank has raised the price target on Quest Diagnostics (NYSE: DGX) from $59 to $64 and maintains its Hold rating.

Morgan Stanley made the following rating changes this morning: Quest Diagnostics (NYSE: DGX) from Underweight to Equal-weight. Morgan Stanley writes, "We are upgrading DGX shares to Equal-weight. Our new rating reflects a more stable utilization environment as we assume volumes have largely...

Piper Jaffray has published a research report on Medical Diagnostics, writing "Our positive 4Q10 STD channel checks suggest a combination of a deductible flush and easier H1N1 comps in December. Not surprisingly, there is concern about the effect of resetting deductibles on 1Q11 trends. We believe...

Piper Jaffray is introducing its F2012 revenue and EPS on shares of Quest Diagnostics Inc. (NYSE: DGX). “We anticipate Quest to benefit from improving physician office trends exiting 2010 and into 2011 as well as progressively easier yoy comps,” Piper Jaffray writes. “We are increasing our price...

Piper Jaffray has raised the price target on Quest Diagnostics (NYSE: DGX) from $51 to $57.

Jefferies has published its research report on Quest Diagnostics (NYSE: DGX) following the Jefferies Healthcare Summit yesterday. According to Jefferies, "Management is working hard to prepare for LT growth by building out its salesforce, expanding its specialty test menu, and improving operating...

Deutsche Bank has published a research report for Quest Diagnostics Inc. (NYSE: DGX) following meetings with the company's management. In the report, Deutsche Bank writes "We recently hosted a mtg at Quest Diagnostics to discuss operating trends & strategic outlook. While NT growth remains...